Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Annexon

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities0.60%
Size of stake in company4.70%
Market capitalization335 mn

Sector

Autoimmune and neurodegenerative diseases

Main candidate

ANX005, ANX007, ANX1502

Main indications

Guillain-Barre Syndrome, Geographic Atrophy and autoimmune diseases

About the company

Annexon Biosciences is a biotechnology company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Annexon’s approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing its mid-to late-stage clinical trials to bring new potential treatments to patients as quickly as possible.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.